Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Theravance Biopharma Inc's Business Segments
Theravance Biopharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 18
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 18 | 100% |
Description of Theravance Biopharma Inc
Theravance Biopharma Inc. is a biopharmaceutical company located in South San Francisco, California. It was founded in 2014 as a spin-off of Theravance Inc., a company that focused on respiratory medicines. Theravance Biopharma aims to develop and commercialize innovative medicines to address serious respiratory and infectious diseases, as well as other therapeutic areas.
The company utilizes a risk-sharing development model, partnering with pharmaceutical companies, such as GlaxoSmithKline (GSK), to share the costs and risks associated with the development and commercialization of its drug candidates. Theravance Biopharma provides its expertise in research and development, while its partners contribute their resources and infrastructure for clinical trials and commercialization.
Theravance Biopharma's research and development efforts primarily focus on the discovery and development of small molecule drugs that target specific mechanisms of disease. Their pipeline includes both proprietary programs and partnered programs with GSK.
In the respiratory disease area, Theravance Biopharma has developed several drug candidates. Its most advanced program is TD-1473, a potential treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. TD-1473 is an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor that is designed to act directly in the gut, minimizing systemic exposure and potentially reducing side effects associated with systemic JAK inhibition.
In addition, Theravance Biopharma has developed TD-8236, which is being investigated for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, the virus responsible for the COVID-19 pandemic. TD-8236 is a lung-selective inhaled pan-JAK inhibitor that aims to reduce the excess inflammation and cytokine storm associated with severe COVID-19.
Theravance Biopharma has also focused on other therapeutic areas outside of respiratory diseases. They have developed TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). This condition is characterized by a drop in blood pressure upon standing, leading to dizziness, lightheadedness, and fainting. TD-9855 is currently being evaluated in Phase 2 studies.
Furthermore, Theravance Biopharma has collaborated with Janssen Biotech (a subsidiary of Johnson & Johnson) in the development of TD-1473 for the treatment of inflammatory bowel disease and TD-5202 for the treatment of hypertension.
Overall, Theravance Biopharma Inc. is focused on developing novel therapies that address significant unmet needs in respiratory, infectious, and other disease areas. Through its partnerships and innovative drug candidates, the company strives to improve patient outcomes and make a positive impact on global health.
The company utilizes a risk-sharing development model, partnering with pharmaceutical companies, such as GlaxoSmithKline (GSK), to share the costs and risks associated with the development and commercialization of its drug candidates. Theravance Biopharma provides its expertise in research and development, while its partners contribute their resources and infrastructure for clinical trials and commercialization.
Theravance Biopharma's research and development efforts primarily focus on the discovery and development of small molecule drugs that target specific mechanisms of disease. Their pipeline includes both proprietary programs and partnered programs with GSK.
In the respiratory disease area, Theravance Biopharma has developed several drug candidates. Its most advanced program is TD-1473, a potential treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. TD-1473 is an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor that is designed to act directly in the gut, minimizing systemic exposure and potentially reducing side effects associated with systemic JAK inhibition.
In addition, Theravance Biopharma has developed TD-8236, which is being investigated for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, the virus responsible for the COVID-19 pandemic. TD-8236 is a lung-selective inhaled pan-JAK inhibitor that aims to reduce the excess inflammation and cytokine storm associated with severe COVID-19.
Theravance Biopharma has also focused on other therapeutic areas outside of respiratory diseases. They have developed TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). This condition is characterized by a drop in blood pressure upon standing, leading to dizziness, lightheadedness, and fainting. TD-9855 is currently being evaluated in Phase 2 studies.
Furthermore, Theravance Biopharma has collaborated with Janssen Biotech (a subsidiary of Johnson & Johnson) in the development of TD-1473 for the treatment of inflammatory bowel disease and TD-5202 for the treatment of hypertension.
Overall, Theravance Biopharma Inc. is focused on developing novel therapies that address significant unmet needs in respiratory, infectious, and other disease areas. Through its partnerships and innovative drug candidates, the company strives to improve patient outcomes and make a positive impact on global health.
As of the last available information, Theravance Biopharma, Inc. is a biopharmaceutical company focused on the development of innovative medicines primarily for respiratory diseases and other conditions. Below is an extensive overview of the segments, products, and services that Theravance Biopharma offers:
Therapeutic Segments
1. Respiratory Diseases: Theravance Biopharma is heavily invested in the development of treatments for chronic respiratory diseases. This includes conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma.
2. Infectious Diseases: The company also engages in the development of therapies for various infectious diseases. This may include work on antibiotics or antiviral agents designed to treat specific pathogens.
3. Central Nervous System (CNS) Disorders: While the primary focus remains on respiratory diseases, the company has explored treatments that may affect the central nervous system.
4. Cardiovascular Conditions: There may be ongoing research or products aimed at managing cardiovascular health within their pipeline.
Key Products
Theravance Biopharma has several significant products that it has developed or partnered to bring to market.
1. Breztri Aerosphere: This is a once-daily inhaler that contains a combination of budesonide and glycopyrrolate. Its used for the maintenance treatment of patients with COPD. The product is designed to improve lung function and decrease the occurrence of COPD exacerbations.
2. Vibativ (telavancin): An injectable antibiotic used to treat complicated skin and skin structure infections, as well as hospital-acquired bacterial pneumonia. It functions by interfering with bacterial cell wall synthesis.
3. Revefenacin (Yupelri): It is a once-daily nebulized bronchodilator for the treatment of COPD, designed to open the airways and improve breathing. This product reflects the companys ongoing commitment to providing alternatives for patients who rely on nebulization therapies.
4. TD-1473: Under development for inflammatory gastrointestinal diseases, this product represents Theravances interest in conditions beyond respiration, particularly in addressing unmet needs in inflammatory bowel diseases.
Research and Development
1. Pipeline Development: The company maintains a robust pipeline of investigational drugs at various stages of clinical trials, including early-stage research and late-stage development. This includes therapeutics for moderate to severe diseases, aimed at offering improved treatment options.
2. Collaborative Agreements: Theravance Biopharma often engages in partnerships with other pharmaceutical companies to co-develop and commercialize products. These agreements can expand the reach and potential market impact of their therapies.
3. Technology Platforms: The company utilizes various technological platforms to enhance drug development, including their proprietary muscle relaxant technology which can improve the delivery and efficacy of inhaled medications.
Services
1. Regulatory Affairs: Theravance Biopharma offers expertise in navigating the complex regulatory environment associated with drug approval processes, ensuring that its products meet all necessary guidelines and quality assurance standards.
2. Clinical Trials Management: The company manages clinical trials efficiently to gather necessary data for product efficacy, safety, and optimal use. This encompasses everything from site selection to patient recruitment and compliance.
3. Medical Affairs: Theravance Biopharma provides medical affairs support to ensure accurate information transfer between the company and healthcare providers, involving education on product use and clinical applications.
4. Commercialization Support: Through strategic marketing and partnerships, Theravance Biopharma assists in the commercialization of its products, ensuring they reach the intended markets effectively.
Conclusion
Theravance Biopharma, Inc. through its extensive pipeline and strategic focus on respiratory and other serious diseases, positions itself as a notable player in the biopharmaceutical industry. The companys combination of innovative product offerings, a strong commitment to research and development, and a range of supporting services highlights its dedication to improving patient care through the discovery and delivery of effective treatments.
Therapeutic Segments
1. Respiratory Diseases: Theravance Biopharma is heavily invested in the development of treatments for chronic respiratory diseases. This includes conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma.
2. Infectious Diseases: The company also engages in the development of therapies for various infectious diseases. This may include work on antibiotics or antiviral agents designed to treat specific pathogens.
3. Central Nervous System (CNS) Disorders: While the primary focus remains on respiratory diseases, the company has explored treatments that may affect the central nervous system.
4. Cardiovascular Conditions: There may be ongoing research or products aimed at managing cardiovascular health within their pipeline.
Key Products
Theravance Biopharma has several significant products that it has developed or partnered to bring to market.
1. Breztri Aerosphere: This is a once-daily inhaler that contains a combination of budesonide and glycopyrrolate. Its used for the maintenance treatment of patients with COPD. The product is designed to improve lung function and decrease the occurrence of COPD exacerbations.
2. Vibativ (telavancin): An injectable antibiotic used to treat complicated skin and skin structure infections, as well as hospital-acquired bacterial pneumonia. It functions by interfering with bacterial cell wall synthesis.
3. Revefenacin (Yupelri): It is a once-daily nebulized bronchodilator for the treatment of COPD, designed to open the airways and improve breathing. This product reflects the companys ongoing commitment to providing alternatives for patients who rely on nebulization therapies.
4. TD-1473: Under development for inflammatory gastrointestinal diseases, this product represents Theravances interest in conditions beyond respiration, particularly in addressing unmet needs in inflammatory bowel diseases.
Research and Development
1. Pipeline Development: The company maintains a robust pipeline of investigational drugs at various stages of clinical trials, including early-stage research and late-stage development. This includes therapeutics for moderate to severe diseases, aimed at offering improved treatment options.
2. Collaborative Agreements: Theravance Biopharma often engages in partnerships with other pharmaceutical companies to co-develop and commercialize products. These agreements can expand the reach and potential market impact of their therapies.
3. Technology Platforms: The company utilizes various technological platforms to enhance drug development, including their proprietary muscle relaxant technology which can improve the delivery and efficacy of inhaled medications.
Services
1. Regulatory Affairs: Theravance Biopharma offers expertise in navigating the complex regulatory environment associated with drug approval processes, ensuring that its products meet all necessary guidelines and quality assurance standards.
2. Clinical Trials Management: The company manages clinical trials efficiently to gather necessary data for product efficacy, safety, and optimal use. This encompasses everything from site selection to patient recruitment and compliance.
3. Medical Affairs: Theravance Biopharma provides medical affairs support to ensure accurate information transfer between the company and healthcare providers, involving education on product use and clinical applications.
4. Commercialization Support: Through strategic marketing and partnerships, Theravance Biopharma assists in the commercialization of its products, ensuring they reach the intended markets effectively.
Conclusion
Theravance Biopharma, Inc. through its extensive pipeline and strategic focus on respiratory and other serious diseases, positions itself as a notable player in the biopharmaceutical industry. The companys combination of innovative product offerings, a strong commitment to research and development, and a range of supporting services highlights its dedication to improving patient care through the discovery and delivery of effective treatments.